Welcome to our dedicated page for Trupanion SEC filings (Ticker: TRUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trupanion, Inc. (NASDAQ: TRUP) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its business as a provider of medical insurance for cats and dogs. These SEC filings cover areas such as financial performance, risk factors, capital structure, governance, and material agreements that shape the company’s operations and its TRUP stock profile.
Key filings for Trupanion include annual reports on Form 10-K, which describe its subscription and other business segments, geographic reach, insurance entities, and risk considerations; and quarterly reports on Form 10-Q, which update investors on revenue from subscription and other business, enrolled pet counts, net income or loss, cash flows, and technology and development spending. Current reports on Form 8-K disclose material events, such as new credit agreements, earnings releases, and board appointments.
For example, Trupanion has used Form 8-K to report entering into a credit agreement with PNC Bank that provides term loan and revolving credit facilities secured by substantially all of the company’s and certain subsidiaries’ assets, and to announce the appointment of a new independent director to its board. Other 8-K filings reference the issuance of press releases detailing quarterly financial results.
Investors can also review Trupanion’s disclosures on non-GAAP financial measures, forward-looking statements, and risk factors, which are discussed in its periodic reports and referenced in earnings-related filings. These documents explain how the company views metrics such as adjusted EBITDA, net acquisition cost, and cash flow, and outline factors that could affect future performance, including claims trends, retention, regulatory constraints, and capital requirements.
On this page, Stock Titan presents Trupanion’s SEC filings alongside AI-powered summaries that highlight the main points of lengthy documents, such as 10-K and 10-Q reports. Users can quickly identify important information on segment performance, debt arrangements, and governance changes, while still having access to the full text of each filing for deeper review.
Trupanion (TRUP) reported Q3 2025 results showing higher revenue and a return to profitability. Revenue was $366,920,000, up from $327,456,000 a year ago. Operating income rose to $5,859,000 from $1,746,000, and net income increased to $5,873,000 with diluted EPS of $0.13.
For the first nine months, revenue reached $1,062,452,000 with net income of $13,803,000, reversing a prior-year loss. Cash from operations was $60,226,000, supporting investments and debt reduction. The balance sheet showed cash and equivalents of $154,773,000, short-term investments of $193,761,000, total assets of $880,173,000, and stockholders’ equity of $368,562,000 as of September 30, 2025.
Subscription segment revenue was $252,697,000 with operating income of $7,826,000; other business revenue was $114,223,000 with an operating loss of $1,967,000. Key metrics included monthly average revenue per pet of $82.01 and average monthly retention of 98.33%. Subsequent to quarter-end, the company refinanced, entering a new $120,000,000 credit facility and used proceeds to retire the prior facility.
Trupanion (TRUP) reported Q3 2025 results showing higher revenue and a return to profitability. Revenue was $366,920,000, up from $327,456,000 a year ago. Operating income rose to $5,859,000 from $1,746,000, and net income increased to $5,873,000 with diluted EPS of $0.13.
For the first nine months, revenue reached $1,062,452,000 with net income of $13,803,000, reversing a prior-year loss. Cash from operations was $60,226,000, supporting investments and debt reduction. The balance sheet showed cash and equivalents of $154,773,000, short-term investments of $193,761,000, total assets of $880,173,000, and stockholders’ equity of $368,562,000 as of September 30, 2025.
Subscription segment revenue was $252,697,000 with operating income of $7,826,000; other business revenue was $114,223,000 with an operating loss of $1,967,000. Key metrics included monthly average revenue per pet of $82.01 and average monthly retention of 98.33%. Subsequent to quarter-end, the company refinanced, entering a new $120,000,000 credit facility and used proceeds to retire the prior facility.
Trupanion entered a new secured credit agreement with PNC Bank, adding a $100.0 million term loan and a $20.0 million revolving facility maturing on November 4, 2028. The company immediately borrowed $100.0 million under the term loan and $15.0 million from the revolver, primarily to repay its 2022 credit agreement, which was simultaneously terminated.
Loans bear interest at SOFR plus 2.75% per year. The term loan requires quarterly principal payments of $2.5 million. Trupanion may prepay or reduce commitments at any time without premium or penalty. The facilities are secured by substantially all assets and include financial covenants limiting indebtedness, liens, investments, and mergers. An event of default allows lenders to terminate revolving commitments and accelerate amounts due. Trupanion also furnished a press release for its quarter ended September 30, 2025.
Trupanion entered a new secured credit agreement with PNC Bank, adding a $100.0 million term loan and a $20.0 million revolving facility maturing on November 4, 2028. The company immediately borrowed $100.0 million under the term loan and $15.0 million from the revolver, primarily to repay its 2022 credit agreement, which was simultaneously terminated.
Loans bear interest at SOFR plus 2.75% per year. The term loan requires quarterly principal payments of $2.5 million. Trupanion may prepay or reduce commitments at any time without premium or penalty. The facilities are secured by substantially all assets and include financial covenants limiting indebtedness, liens, investments, and mergers. An event of default allows lenders to terminate revolving commitments and accelerate amounts due. Trupanion also furnished a press release for its quarter ended September 30, 2025.
Trupanion, Inc. filed a Form 3 initial statement for Bradley S. Powell, identifying him as a Director. The filing states “No securities are beneficially owned” as of the event date 10/29/2025, and indicates it was filed by one reporting person.
Trupanion, Inc. filed a Form 3 initial statement for Bradley S. Powell, identifying him as a Director. The filing states “No securities are beneficially owned” as of the event date 10/29/2025, and indicates it was filed by one reporting person.
Trupanion appointed Bradley S. Powell to its board of directors. Powell, 65, is an independent director under Nasdaq rules and brings extensive public-company finance experience. He served as Chief Financial Officer of Expeditors International from 2008 to 2025 and previously was CFO of Eden Bioscience from 1998 to 2008, where he led its 2000 IPO.
Powell will serve until the 2026 annual meeting of stockholders. He has no arrangements related to his appointment, no family relationships with Trupanion’s leadership, and no material interests in related-party transactions. Trupanion entered into its standard indemnification agreement with him, and he will participate in the Compensation Program for Non-Employee Directors.
Trupanion, Inc. (TRUP) CEO and director Margaret Tooth reported a Rule 10b5-1(c) trade on 10/27/2025.
She exercised 6,000 options at $8.93 and then sold 6,000 shares at a weighted average price of $43.7233 and 2,884 shares at a weighted average price of $43.7424. The sales were executed in multiple transactions within stated price ranges under a pre‑arranged trading plan adopted on June 6, 2025.
Following these transactions, Tooth beneficially owned 141,345 shares of common stock directly and held 16,000 stock options outstanding. The referenced stock option grant is fully vested and expires on 12/21/2025.
Tarmac DLTFM Limited reports beneficial ownership of 3,575,538 shares of Trupanion, Inc. common stock, representing 8.3% of the outstanding class based on 42,994,675 shares outstanding as of July 31, 2025. The filing states Tarmac holds sole voting and dispositive power over these shares and that the securities were not acquired to change or influence control of the company. The statement uses the Schedule 13G format and is signed by a director, indicating passive investor reporting rather than an active acquisition or control intent.
Form 144 filed for Trupanion, Inc. (TRUP) reporting a proposed sale of common stock. The filing lists 8,961 shares scheduled for sale on 09/25/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $375,317.93. The filing discloses the acquisition history for those shares: restricted stock grants on 08/25/2021 (1,317 shares) and 02/25/2022 (1,644 shares), and a stock option exercise on 09/25/2025 for 6,000 shares paid in cash. No securities were reported sold in the past three months. The filer affirms no undisclosed material nonpublic information.
Trupanion insider sale notice: This Form 144/A reports a proposed sale of 30,369 shares of Trupanion common stock via Fidelity Brokerage Services (245 Summer Street, Boston, MA) with an aggregate market value of $1,357,943.00. The shares are listed as to be sold approximately on 09/04/2025 on NASDAQ. The filing lists the acquisition history for these shares showing multiple stock awards and one stock option from Trupanion dated between 2018 and 2025, with amounts for each award. The filing also discloses a sale during the past three months: Darryl Rawlings (c/o Trupanion) sold 19,631 shares on 09/03/2025 for gross proceeds of $878,487.25. The filer certifies no undisclosed material adverse information.
Trupanion insider sale notice: This Form 144/A reports a proposed sale of 30,369 shares of Trupanion common stock via Fidelity Brokerage Services (245 Summer Street, Boston, MA) with an aggregate market value of $1,357,943.00. The shares are listed as to be sold approximately on 09/04/2025 on NASDAQ. The filing lists the acquisition history for these shares showing multiple stock awards and one stock option from Trupanion dated between 2018 and 2025, with amounts for each award. The filing also discloses a sale during the past three months: Darryl Rawlings (c/o Trupanion) sold 19,631 shares on 09/03/2025 for gross proceeds of $878,487.25. The filer certifies no undisclosed material adverse information.
Trupanion insider sale notice: This Form 144/A reports a proposed sale of 30,369 shares of Trupanion common stock via Fidelity Brokerage Services (245 Summer Street, Boston, MA) with an aggregate market value of $1,357,943.00. The shares are listed as to be sold approximately on 09/04/2025 on NASDAQ. The filing lists the acquisition history for these shares showing multiple stock awards and one stock option from Trupanion dated between 2018 and 2025, with amounts for each award. The filing also discloses a sale during the past three months: Darryl Rawlings (c/o Trupanion) sold 19,631 shares on 09/03/2025 for gross proceeds of $878,487.25. The filer certifies no undisclosed material adverse information.
Darryl Rawlings, a director of Trupanion, Inc. (TRUP), reported two open-market sales of common stock. On 09/03/2025 he sold 19,631 shares at a weighted-average price of $44.7876, after which his indirect beneficial ownership through Kuyashii Primary Equities LLC was 1,443,650 shares. On 09/04/2025 he sold an additional 30,369 shares at a weighted-average price of $44.7002, leaving 1,413,281 indirectly beneficially owned. The Form 4 was signed by Christina Poler as attorney-in-fact on 09/05/2025. Footnotes state each reported price is a weighted average from multiple transactions and that the reporting person will provide transaction-level price breakdowns on request.
Form 144 filing for Trupanion, Inc. (TRUP) shows a proposed sale of 30,369 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $135,794.30, and an approximate sale date of 09/04/2025 on NASDAQ. The filing lists the total shares outstanding as 42,994,675. Acquisition details show these shares were received primarily as stock awards from Trupanion on multiple dates between 2018 and 2025, and one small stock option exercise paid by cash/check. The filing also discloses a sale on 09/03/2025 by Rawlings Darryl of 19,631 shares generating $878,487.25 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.